Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 7 Mendeley

So far, Altmetric has seen 1 X post from an account with 6,541 followers.

New research: Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report: Background PARP inhibitors have been approved as targeted therapy for BRCA-deficient metastatic ovarian… https://t.

26 Feb 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.